BCM
BML Capital Management Portfolio holdings
AUM
$131M
This Quarter Return
+1.98%
1 Year Return
+89.45%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$116M
AUM Growth
+$116M
(+11%)
Cap. Flow
-$65.9M
Cap. Flow
% of AUM
-56.95%
Top 10 Holdings %
Top 10 Hldgs %
67.62%
Holding
35
New
10
Increased
4
Reduced
8
Closed
4
Top Buys
| 1 |
iShares 0-3 Month Treasury Bond ETF
SGOV
|
$12.6M |
| 2 |
SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
|
$9.18M |
| 3 |
CYT
Cyteir Therapeutics, Inc. Common Stock
CYT
|
$5.73M |
| 4 |
Tourmaline Bio
TRML
|
$3.63M |
| 5 |
EMBK
Embark Technology, Inc. Common Stock
EMBK
|
$3.61M |
Top Sells
| 1 |
Enliven Therapeutics
ELVN
|
$61.4M |
| 2 |
Carisma Therapeutics
CARM
|
$24.2M |
| 3 |
Abercrombie & Fitch
ANF
|
$7.64M |
| 4 |
Verrica Pharmaceuticals
VRCA
|
$6.24M |
| 5 |
Disc Medicine
IRON
|
$6.18M |
Sector Composition
| 1 | Healthcare | 53.31% |
| 2 | Consumer Discretionary | 14.79% |
| 3 | Technology | 5.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$42.1B
| $18.4M | 15.87% | 200,000 +100,000 | +100% | +$9.18M |
|
|
2
iShares 0-3 Month Treasury Bond ETF
SGOV
$56.1B
| $12.6M | 10.87% | +125,000 | New | +$12.6M |
|
3
Tilly's
TLYS
$59.4M
| $8.9M | 7.7% | 1,154,844 | – | – |
|
|
4
Abercrombie & Fitch
ANF
$4.46B
| $8.21M | 7.09% | 295,778 -275,339 | -48% | -$7.64M |
|
|
CYT
5
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
| $5.73M | 4.95% | +3,146,296 | New | +$5.73M |
|
|
PRDS
6
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $5.26M | 4.55% | 3,986,577 -881,407 | -18% | -$1.16M |
|
7
Adverum Biotechnologies
ADVM
$64.6M
| $5.07M | 4.38% | 7,067,179 | – | – |
|
|
CLYM
8
Climb Bio, Inc. Common Stock
CLYM
$151M
| $4.81M | 4.16% | 1,658,170 -166,964 | -9% | -$484K |
|
9
Athira Pharma
ATHA
$15.3M
| $4.66M | 4.03% | 1,864,907 +1,150,144 | +161% | +$2.88M |
|
|
10
Enliven Therapeutics
ELVN
$1.2B
| $4.65M | 4.02% | 212,179 -2,805,595 | -93% | -$61.4M |
|
|
STSA
11
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
| $4.5M | 3.89% | 6,440,000 | – | – |
|
|
12
Disc Medicine
IRON
$2.07B
| $4.41M | 3.81% | 208,161 -291,839 | -58% | -$6.18M |
|
|
13
Tourmaline Bio
TRML
$601M
| $3.63M | 3.14% | +1,929,484 | New | +$3.63M |
|
|
EMBK
14
DELISTED
Embark Technology, Inc. Common Stock
EMBK
| $3.61M | 3.12% | +1,285,390 | New | +$3.61M |
|
|
MTCR
15
DELISTED
Metacrine, Inc. Common Stock
MTCR
| $3.52M | 3.04% | 6,167,458 | – | – |
|
16
Oramed Pharmaceuticals
ORMP
$90.2M
| $2.96M | 2.56% | +1,355,925 | New | +$2.96M |
|
17
Astrotech Corp
ASTC
$8.72M
| $2.35M | 2.03% | 220,410 | – | – |
|
|
JNCE
18
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $2.01M | 1.74% | +1,087,961 | New | +$2.01M |
|
19
Forte Biosciences
FBRX
$137M
| $1.75M | 1.51% | 1,735,075 +273,711 | +19% | +$276K |
|
|
ORKA
20
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $1.41M | 1.22% | 706,930 -151,326 | -18% | -$301K |
|
|
21
Carisma Therapeutics
CARM
$8.98M
| $1.28M | 1.1% | 411,398 -7,816,571 | -95% | -$24.2M |
|
22
Retractable Technologies
RVP
$25.1M
| $1.17M | 1.01% | 668,575 | – | – |
|
|
23
Verrica Pharmaceuticals
VRCA
$52.8M
| $975K | 0.84% | 150,000 -960,605 | -86% | -$6.24M |
|
24
Surrozen
SRZN
$104M
| $899K | 0.78% | +1,494,037 | New | +$899K |
|
25
Milestone Pharmaceuticals
MIST
$156M
| $867K | 0.75% | 220,000 +40,000 | +22% | +$158K |
|